Skip to main content

Table 4 PTGS2 rs5275 genotype and breast cancer risk within the NHS1, NHS2, WHS, and pooled data

From: A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study

Study

Genotype

Cases (percentage)

Controls (percentage)

OR (95% CI)a

NHS1

T/T

541 (43.3)

699 (40.6)

1.00 (reference)

 

T/C

567 (45.4)

808 (47.0)

0.89 (0.75–1.04)

 

C/C

141 (11.3)

213 (12.4)

0.80 (0.62–1.03)

    

p trend = 0.05

NHS2

T/T

140 (46.5)

270 (44.3)

1.00 (reference)

 

T/C

131 (43.5)

259 (42.5)

0.97 (0.72–1.31)

 

C/C

30 (10.0)

81 (13.3)

0.72 (0.45–1.15)

    

p trend = 0.26

WHS

T/T

281 (43.6)

278 (42.7)

1.00 (reference)

 

T/C

296 (46.0)

294 (45.2)

0.99 (0.78–1.26)

 

C/C

67 (10.4)

79 (12.1)

0.86 (0.58–1.25)

    

p trend = 0.53

Pooled

T/T

962 (43.8)

1,246 (41.8)

1.00 (reference)

 

T/C

994 (45.3)

1,361 (45.7)

0.93 (0.82–1.05)

 

C/C

238 (10.8)

373 (12.5)

0.80 (0.66–0.97)

    

p trend = 0.02

  1. aUnconditional logistic regression controlled for age, age at first birth and parity, menopausal status at diagnosis, history of benign breast disease, and family history of breast cancer. CI, confidence interval; NHS, Nurses' Health Study; OR, odds ratio; PTGS2, prostaglandin endoperoxide synthase 2; WHS, Harvard Women's Health Study.